… Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, … MEK2-Q60P
mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor …

… MEK inhibitor approved for the treatment of BRAF-mutated metastatic melanoma not previously
treated with BRAF inhibitors, … -noncompetitive selective inhibitor of MEK1 and MEK2. In …

… In this review, we discuss the preclinical data, clinical development, and potential use of
novel MEK inhibitor binemetinib, particularly in the setting of NRAS mutant melanoma. …

… Trametinib (Mekinist™) is a reversible and highly selective allosteric inhibitor of MEK1 and
MEK2 with anticancer activity against metastatic melanoma carrying the BRAF V600 mutation…

… -mutant metastatic melanoma. New evidence suggests that the combination of BRAF and
MEK inhibitors … Trametinib is an orally available, potent, selective inhibitor of MEK1 and MEK2 …

… , non-ATP-competitive inhibitor of both MEK1 and MEK2, was one of the first MEK-targeting
agents to … For NRAS-mutant melanomas, a combination of a MEK inhibitor and a cell cycle …

… , dual inhibition of the MAPK pathway with the combination of BRAF and MEK inhibitors in
… In this article, clinical data on dual BRAF and MEK inhibition in advanced melanoma will be …

… to MEK inhibition, we examined the effects of MEK inhibition on ex vivo melanoma cultures
… for genetic alterations affecting MEK1 (and conceivably MEK2) in cases where resistance …

… For instance, MEK2 mutations are favoured over MEK1 mutations in combination resistant
tumours and BRAF splice variants, which appear to induce low levels of MAPK signalling, are …

… MEK inhibition has emerged as the key component for the treatment of BRAF-mutant metastatic
melanoma… and CRAF), two subtypes of MEK (ME1 and MEK2), and two subtypes of ERK (…